Skip to main content
. Author manuscript; available in PMC: 2020 Feb 12.
Published in final edited form as: Nat Med. 2019 Aug 12;25(9):1422–1427. doi: 10.1038/s41591-019-0542-z

Extended Data Fig. 2: Radiologic response to combined RAF/MEK inhibition in Patient 1 correlates with decreased allele frequency of the TRK fusion in cfDNA.

Extended Data Fig. 2:

Graph depicting the allele frequencies of truncal NTRK fusion in the cfDNA of the CTRC-NTRK1 positive pancreatic adenocarcinoma) patient (Patient 1) while treated with LOXO-195 and the combination of dabrafenib and trametinib. The time on treatment, best clinical response (SD: stable disease based on RECIST v1.1 criteria) and the time of progression (POD) for each of the indicated therapeutic regimens are displayed.